Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 30, 2025Frontiers in ImmunologyOpen Access

Preoperative TACE with PD-1 inhibitors and TKIs in beyond “up-to-seven” hepatocellular carcinoma: a propensity score matched analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

DZDeyuan ZhongYLYuxin LiangYCYa-hui Chen

Discussion

Loading...

Member takes

Overview

Observational analysis showed improved overall survival in hepatocellular carcinoma patients undergoing neoadjuvant TACE.

Key Points

  • The studying of neoadjuvant TACE treatment resulted in better overall survival compared to surgery alone.
  • The median overall survival was significantly higher in the neoadjuvant group, seen in a duration of 26 months.
  • Analysis involved a retrospective cohort of 126 patients with a matched design to reduce confounders.
  • The findings suggest that neoadjuvant therapy may be advantageous for hepatocellular carcinoma surgeries.

Cite This Study

Zhong et al. (2025) studied this question.

synapsesocial.com/papers/692b9d7b1d383f2b2a3794f2https://doi.org/10.3389/fimmu.2025.1657371
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Whether Adjuvant TACE Plus TKI Therapy is More Effective Than TACE Alone in HCC Patients at High Risks of Recurrence Following Radical Hepatectomy2025
  2. 2Efficacy and Safety of PD-1 Inhibitors Combined with Transarterial Chemoembolization (TACE) and targeted Therapy in Advanced Primary Hepatocellular Carcinoma2025
  3. 3Anti-PD-1 therapy for preventing recurrence and improving survival in hepatocellular carcinoma patients after hepatectomy2025
  4. 4PERI-START: a phase II trial of perioperative TACE, tislelizumab, and lenvatinib in early-stage hepatocellular carcinoma2025
  5. 5The Impact of Local Ablative Therapies as Bridging Treatment on Overall Survival Following Liver Transplantation in Patients with HCC2025